論文

査読有り
2016年8月

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation

ACTA MEDICA OKAYAMA
  • Masahiro Osawa
  • ,
  • Kadoaki Ohashi
  • ,
  • Toshio Kubo
  • ,
  • Eiki Ichihara
  • ,
  • Saburo Takata
  • ,
  • Nagio Takigawa
  • ,
  • Minoru Takata
  • ,
  • Mitsune Tanimoto
  • ,
  • Katsuyuki Kiura

70
4
開始ページ
243
終了ページ
253
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18926/AMO/54499
出版者・発行元
OKAYAMA UNIV MED SCHOOL

Vandetanib (Zactima (TM)) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.

リンク情報
DOI
https://doi.org/10.18926/AMO/54499
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000384748600003&DestApp=WOS_CPL
ID情報
  • DOI : 10.18926/AMO/54499
  • ISSN : 0386-300X
  • Web of Science ID : WOS:000384748600003

エクスポート
BibTeX RIS